Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Amgen.

Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed Disease

Release Date: November 30, 2018
Expiration Date: November 30, 2019
Media: Internet - based

Activity Overview

This continuing medical education (CME)-certified activity, Advances In™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed Disease, will provide you with clinically important information about T-cell engaging immunotherapy that you can use in the management of your patients with minimal residual disease–positive acute lymphoblastic leukemia (MRD+ ALL). It will focus on the evolution of bispecific T-cell engager (BiTE) therapy and its growing potential in treating patients with ALL. Listen to experts as they share clinical pearls regarding the incorporation of CAR-T, ADC’s, and BiTE therapies into their clinics. Topics will include the rationale for use of these agents, current and emerging strategies for selecting patients who can benefit from this approach, and placement of current data sets into the context of the treatment landscape. Moreover, you’ll learn about the identification, recognition, and management of immune-related toxicities. Start now to gain insights into this cutting-edge treatment approach.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Amgen.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational program is directed toward community oncologists, medical oncologists, and hematologists who treat patients with ALL. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals (HCPs) involved in the treatment of ALL are also invited to participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Outline current treatment standards for ALL and the mechanistic rationale for applying T-cell engaging immunotherapy in ALL management
  2. Illustrate clinical decision-making concerning the use of T-cell engaging immunotherapy in patients with MRD+ ALL following induction therapy
  3. Evaluate clinical trial evidence from investigations that have evaluated T-cell engaging immunotherapy in patients with ALL
  4. Incorporate key findings from recent clinical trials on the use of T-cell engaging immunotherapy treatment strategies for patients with ALL in frontline and relapsed/refractory settings

Faculty, Staff, and Planners' Disclosures

Faculty

Elias Jabbour, MD
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
 
 

Disclosures: Grant/Research Support: Amgen, Pfizer, Takeda, Adaptive Biotechnologies, Novartis, Spectrum, AbbVie, Bristol-Myers Squibb

Jae H. Park, MD
Memorial Sloan Kettering Cancer Center
New York, NY
 
 
 

Disclosures: Consultant: Amgen, Novartis, Adaptive Biotechnologies, Kite Pharma, Juno Therapeutics, Pfizer

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By